Your browser doesn't support javascript.
loading
Lymphocyte Level at Diagnosis in Hodgkin lymphoma: Could It be an Indicator of the Stage at Initial Diagnosis?
Goze, Hasan; Cinli, Tahir Alper; Baydilli, Kursad Nuri; Serin, Istemi.
Afiliación
  • Goze H; Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
  • Cinli TA; Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
  • Baydilli KN; Department of Biostatistics and Medical Informatics, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Serin I; Department of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
Int J Hematol Oncol Stem Cell Res ; 18(1): 14-32, 2024 Jan 01.
Article en En | MEDLINE | ID: mdl-38680717
ABSTRACT

Background:

Despite the existence of standard risk classification systems and effective treatment approaches, 34% to 37% of advanced-stage Hodgkin lymphomas (HLs) either relapse or progress. Our goal in our study was to show the relationship between initial lymphocyte count and stage while examining their effects on prognosis. The initial lymphocyte count, which is proven in advanced-stage patients, could be an important factor in terms of showing the prognosis in the early stage. Materials and

Methods:

Our study included 190 patients diagnosed with HL in our hospital between January 2010 and September 2020. HL subtypes, diagnosis stages, presence of bulky or mediastinal masses, lymphadenopathy areas, and demographic data of patients, such as age and sex. The aim was to obtain a cutoff in the statistical analysis performed to explore the relationship between lymphocyte level and stage, which is the main hypothesis of the study.

Results:

Of the 190 patients evaluated, 77 were female (40.5%) and 113 were male (59.5%). To obtain a cutoff in terms of lymphocyte level and stage relationship, a value of 2380/mm3 and below was found to be associated with stage 3-4 disease with a sensitivity of 86.44% and a specificity of 33.3% (AUC 0.613 (0.539-0.682), p<0.007).

Conclusion:

This result can be improved in combination with conventional imaging methods used for staging purposes. Further studies may shed light on staging and especially the diagnosis of advanced-stage disease with high sensitivity.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Int J Hematol Oncol Stem Cell Res Año: 2024 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Int J Hematol Oncol Stem Cell Res Año: 2024 Tipo del documento: Article País de afiliación: Turquía